Concepedia

Dale A. Mais

DA

Statistics

Publications

6

Citations

171

H-Index

6

Active since

2003

Affiliations

Ligand Pharmaceuticals (United States)(Current)

Eli Lilly (United States)

Dale A. Mais is an author at Ligand Pharmaceuticals (United States) specializing in medicinal chemistry, pharmacy, and drug design.

Publications per year

2003–2004

6

Publications

6

Novel (2<i>E</i>,4<i>E</i>,6<i>Z</i>)-7-(2-Alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic Acid Retinoid X Receptor Modulators Are Active in Models of Type 2 Diabetes

Pierre‐Yves Michellys, Robert Ardecky, J. H. Chen et al. · Journal of Medicinal Chemistry · 2003 · 51 citations · Full text

, , +13

Design, Synthesis, and Structure−Activity Relationship Studies of Novel 6,7-Locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic Acids

Pierre‐Yves Michellys, Robert Ardecky, Jyun‐Hung Chen et al. · Journal of Medicinal Chemistry · 2003 · 33 citations · Full text

, , +13

Design and synthesis of novel RXR-selective modulators with improved pharmacological profile

Pierre‐Yves Michellys, Marcus F. Boehm, Jyun‐Hung Chen et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 28 citations · Full text

, , +11

Design, synthesis and structure–activity relationship of novel RXR-selective modulators

Pierre‐Yves Michellys, Jennifer D’Arrigo, Timothy A. Grese et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 25 citations · Full text

, , +10

Design and synthesis of fluorinated RXR modulators

Douglas L. Gernert, Rose T. Ajamie, R.A. Ardecky et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 21 citations · Full text

, , +5

1–5 of 6